



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Ocriplasmin (Jetrea®)
Indication under review	NICE TA 297: Ocriplasmin for the treatment of vitreomacular traction.
Policy No:	APC 032
Date of Issue:	January 2014
Review Date:	January 2017
Policy Statement: Ocriplasmin is recommended as an option for treating vitreomacular traction when used in accordance with NICE TA 297, see points below.	
Traffic Light Status	Red
Key Points considered: Ocriplasmin is recommended as an option for treating vitreomacular traction in adults, only if: an epiretinal membrane is not present and they have a stage II full-thickness macular hole with a diameter of 400 micrometres or less and/or they have severe symptoms.	
References: NICE TA 297 accessible via http://www.nice.org.uk/nicemedia/live/14305/65827/65827.pdf	
Date taken to APC:	8 th January 2014
Date Ratified by GP MMC on Behalf of the Board:	15 th January 2014